Anti-acetylcholine receptor antibodies

Area of Science:

• Neurology
• Immunology
• Neuroscience

Background:

• Myasthenia gravis (MG) is a neuromuscular disorder characterized by impaired neuromuscular transmission.
• Early hypotheses suggested a humoral factor's involvement, which has been substantiated by antibody detection.

Purpose of the Study:

• To confirm the role of anti-acetylcholine receptor (anti-AChR) antibodies in myasthenia gravis.
• To investigate the relationship between anti-AChR antibody levels, disease severity, and treatment outcomes.

Main Methods:

• Detection of anti-AChR antibodies in patient serum.
• Plasma exchange to assess the relationship between antibody levels and muscle strength.
• Monitoring anti-AChR antibody titers in patients undergoing thymectomy and immunosuppressive therapy.
• In vitro studies of anti-AChR antibody synthesis by thymic and peripheral lymphocytes.

Main Results:

• Anti-AChR antibodies are detected in 85-90% of generalized MG cases and 75% of ocular MG cases.
• Serum anti-AChR antibody levels typically show an inverse relationship with muscle strength.
• Successful thymectomy and immunosuppressive treatment correlate with a decline in anti-AChR antibody titers.
• The antibody is heterogeneous and contributes to acetylcholine receptor (AChR) loss through multiple mechanisms.

Conclusions:

• Anti-AChR antibodies are a key factor in myasthenia gravis pathogenesis.
• Antibody levels serve as a potential biomarker for disease activity and treatment efficacy.
• Multiple mechanisms may contribute to the breakdown of tolerance, leading to anti-AChR antibody production in MG.